2-fluoro-N-(pyridin-3-ylmethyl)-9H-purin-6-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-fluoro-N-(pyridin-3-ylmethyl)-9H-purin-6-amine
• 英文别名: 2-fluoro-6-[(pyridin-3-ylmethyl)-amino]purine；(2-fluoro-9H-purin-6-yl)-pyridin-3-ylmethyl-amine；2-fluoro-N-(pyridin-3-ylmethyl)-7H-purin-6-amine
• 化学式: C₁₁H₉FN₆
• 分子量: 244.231
• InChiKey: YIDSLZLYPNKFDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-fluoro-N-(pyridin-3-ylmethyl)-9H-purin-6-amine 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 2,4-滴二甲胺盐 、 二甲基亚砜 、 正丁醇 为溶剂， 反应 120.0h， 生成 2-[(1R,2RS)-1-ethyl-2-hydroxy-3-methylbutylamino]-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]purine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

  摘要：

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.051
• 作为产物：
  描述：

  3-氨甲基吡啶 、 2-氟-6-氯嘌呤 在 N,N-二异丙基乙胺 作用下， 以 正丁醇 为溶剂， 反应 18.5h， 以42%的产率得到2-fluoro-N-(pyridin-3-ylmethyl)-9H-purin-6-amine
  参考文献：
  名称：

  [EN] IMAGING AGENTS FOR NEURAL FLUX
  [FR] AGENTS D'IMAGERIE POUR FLUX NEURONAL

  摘要：

  本文提供了用于非侵入性成像技术的放射性标记化合物。本文提供的一种示例性放射性标记化合物可用作正电子发射断层扫描的放射示踪剂。本申请还提供了用于治疗中枢神经系统疾病或外周神经系统疾病的未标记化合物。还提供了制备放射性标记化合物、制备未标记化合物以及使用标记化或未标记化化合物的诊断方法。

  公开号：

  WO2016011394A1

文献信息

• [EN] IMAGING AGENTS FOR NEURAL FLUX<br/>[FR] AGENTS D'IMAGERIE POUR FLUX NEURONAL
  申请人：GEN HOSPITAL CORP

  公开号：WO2016011394A1

  公开（公告）日：2016-01-21

  Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.

  本文提供了用于非侵入性成像技术的放射性标记化合物。本文提供的一种示例性放射性标记化合物可用作正电子发射断层扫描的放射示踪剂。本申请还提供了用于治疗中枢神经系统疾病或外周神经系统疾病的未标记化合物。还提供了制备放射性标记化合物、制备未标记化合物以及使用标记化或未标记化化合物的诊断方法。
• NEW PURINE DERIVATIVES
  申请人：FISCHER Peter Martin

  公开号：US20090325983A1

  公开（公告）日：2009-12-31

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R 1 and R 2 is methyl, ethyl or isopropyl, and the other is H; R 3 and R 4 are each independently H, branched or unbranched C 1 -C 6 alkyl, or aryl, and wherein at least one of R 3 and R 4 is other than H; R 5 is a branched or unbranched C 1 -C 5 alkyl group or a C 1 -C 6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R 6 , R 7 , R 8 and R 9 are each independently H, halogen, NO 2 , OH, OMe, CN, NH 2 , COOH, CONH 2 , or SO 2 NH 2 . A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基，且其中至少一个不是氢；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团都可以选择地用一个或多个OH基团进行取代；R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。本发明的另一个方面涉及包含上述公式1化合物的制药组合物，以及在治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病中使用上述化合物的用途。
• COMPOUNDS
  申请人：SHELDRAKE Peter William

  公开号：US20100093769A1

  公开（公告）日：2010-04-15

  The present invention relates to compounds of formula (I) wherein: R 1 and R 2 are each independently H, alkyl or haloalkyl; R 3 and R 4 are each independently H, alkyl, haloalkyl or aryl; R 5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R 6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR 9 ; R 7 , R 8 and each R 9 are independently H, alkyl or haloalkyl, wherein at least one of R 7 , R 8 and each R 9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及式(I)化合物，其中： R1和R2各自独立地为H、烷基或卤代烷基； R3和R4各自独立地为H、烷基、卤代烷基或芳基； R5为烷基或环烷基或环烷基烷基，每个基团可以选择性地被一个或多个OH基团取代； R6选自环丙基氨基、环丙基甲基氨基、环丁基氨基、环丁基甲基氨基和其中的一个，其中X、Y和Z中的一个为N，其余为CR9； R7、R8和每个R9各自独立地为H、烷基或卤代烷基，其中至少一个R7、R8和每个R9不是H。 本发明的另一个方面涉及包含式(I)化合物的药物组合物，以及使用该化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病的方法。
• Purine derivatives
  申请人：Cyclacel Limited

  公开号：US07582642B2

  公开（公告）日：2009-09-01

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基，并且至少有一个R3和R4不是氢；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团可以选择性地取代一个或多个OH基团；R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。 本发明的另一个方面涉及包含公式1化合物的药物组合物，并且使用所述化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病。
• Trisubstituted purine derivatives
  申请人：Sheldrake Peter William

  公开号：US08592581B2

  公开（公告）日：2013-11-26

  The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及式（I）的化合物，其中： R1和R2各自独立地为H、烷基或卤代烷基； R3和R4各自独立地为H、烷基、卤代烷基或芳基； R5为烷基或环烷基或环烷基烷基，其中每个基团可以选择地被一个或多个OH基团取代； R6选择自环丙氨基、环丙甲基氨基、环丁氨基、环丁甲基氨基和其中X、Y和Z中的一个为N，其余为CR9； R7、R8和每个R9各自独立地为H、烷基或卤代烷基，其中至少一个R7、R8和每个R9不是H。 本发明的另一个方面涉及包含式（I）的化合物的制药组合物，以及使用该化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病的用途。